453 related articles for article (PubMed ID: 35385089)
41. A comparison of post-transplantation cyclophosphamide versus antithymocyte-globulin in patients with hematological malignancies undergoing HLA-matched unrelated donor transplantation.
Lee MW; Yeon SH; Seo WH; Ryu H; Lee HJ; Yun HJ; Jo DY; Song IC
Medicine (Baltimore); 2020 Aug; 99(34):e21571. PubMed ID: 32846764
[TBL] [Abstract][Full Text] [Related]
42. In vivo T cell depletion with low-dose rabbit antithymocyte globulin results in low transplant-related mortality and low relapse incidence following unrelated hematopoietic stem cell transplantation.
Nachbaur D; Eibl B; Kropshofer G; Meister B; Mitterschiffthaler A; Schennach H; Fischer G; Kopp M; Gunsilius E; Gastl G
J Hematother Stem Cell Res; 2002 Aug; 11(4):731-7. PubMed ID: 12201962
[TBL] [Abstract][Full Text] [Related]
43. Risk factors and survival analysis of human leukocyte antigen loss in relapsed acute myeloid leukaemia/myelodysplastic syndrome patients after allogeneic haematopoietic stem cell transplantation.
Zhang T; Zhang Y; Zhou M; Zhang Z; Bao X; Wen L; Feng Y; Li X; Zhai M; Liu X; Zeng Z; Wu X; Chen S
Br J Haematol; 2024 Apr; 204(4):1402-1413. PubMed ID: 38327115
[TBL] [Abstract][Full Text] [Related]
44. HLA-haploidentical donor lymphocyte infusions for patients with relapsed hematologic malignancies after related HLA-haploidentical bone marrow transplantation.
Zeidan AM; Forde PM; Symons H; Chen A; Smith BD; Pratz K; Carraway H; Gladstone DE; Fuchs EJ; Luznik L; Jones RJ; Bolaños-Meade J
Biol Blood Marrow Transplant; 2014 Mar; 20(3):314-8. PubMed ID: 24296490
[TBL] [Abstract][Full Text] [Related]
45. Outcomes of peripheral blood stem cell transplantation patients from HLA-mismatched unrelated donor with antithymocyte globulin (ATG)-Thymoglobulin versus ATG-Fresenius: a single-center study.
Huang W; Zhao X; Tian Y; Cao T; Li Y; Liu Z; Jing Y; Wang S; Gao C; Yu L
Med Oncol; 2015 Feb; 32(2):465. PubMed ID: 25588925
[TBL] [Abstract][Full Text] [Related]
46. Optimal dose of rabbit thymoglobulin in conditioning regimens for unmanipulated, haploidentical, hematopoietic stem cell transplantation: Long-term outcomes of a prospective randomized trial.
Chang YJ; Wang Y; Mo XD; Zhang XH; Xu LP; Yan CH; Chen H; Chen YH; Chen Y; Han W; Wang FR; Wang JZ; Liu KY; Huang XJ
Cancer; 2017 Aug; 123(15):2881-2892. PubMed ID: 28301690
[TBL] [Abstract][Full Text] [Related]
47. Combining post-transplant cyclophosphamide with antithymocyte globulin for graft-versus-host disease prophylaxis in hematological malignancies.
Duléry R; Brissot E; Mohty M
Blood Rev; 2023 Nov; 62():101080. PubMed ID: 37085459
[TBL] [Abstract][Full Text] [Related]
48. A high antithymocyte globulin dose increases the risk of relapse after reduced intensity conditioning HSCT with unrelated donors.
Remberger M; Ringdén O; Hägglund H; Svahn BM; Ljungman P; Uhlin M; Mattsson J
Clin Transplant; 2013; 27(4):E368-74. PubMed ID: 23701240
[TBL] [Abstract][Full Text] [Related]
49. Bortezomib-based graft-versus-host disease prophylaxis in HLA-mismatched unrelated donor transplantation.
Koreth J; Stevenson KE; Kim HT; McDonough SM; Bindra B; Armand P; Ho VT; Cutler C; Blazar BR; Antin JH; Soiffer RJ; Ritz J; Alyea EP
J Clin Oncol; 2012 Sep; 30(26):3202-8. PubMed ID: 22869883
[TBL] [Abstract][Full Text] [Related]
50. Does anti-thymocyte globulin have a place in busulfan/fludarabine conditioning for matched related donor hematopoietic stem cell transplantation?
Ji YS; Lee MS; Min CW; Park SK; Kim SH; Yun J; Kim HJ; Kim KH; Kim CK; Lee KT; Won JH; Hong DS
Korean J Intern Med; 2016 Jul; 31(4):750-61. PubMed ID: 27017944
[TBL] [Abstract][Full Text] [Related]
51. Clonal evolution including partial loss of human leukocyte antigen genes favoring extramedullary acute myeloid leukemia relapse after matched related allogeneic hematopoietic stem cell transplantation.
Stölzel F; Hackmann K; Kuithan F; Mohr B; Füssel M; Oelschlägel U; Thiede C; Röllig C; Platzbecker U; Schetelig J; Illmer T; Schaich M; Seliger B; Hartmann A; Baretton G; Zietz C; Ehninger G; Schrock E; Bornhäuser M
Transplantation; 2012 Apr; 93(7):744-9. PubMed ID: 22314337
[TBL] [Abstract][Full Text] [Related]
52. Comparison of rabbit ATLG and ATG for GVHD prophylaxis in hematological malignancies with haploidentical hematopoietic stem cell transplantation.
Tian Z; Man Q; Yang Y; Guan H; Wang Y; Luo R; Wang J
Ann Hematol; 2024 May; 103(5):1729-1736. PubMed ID: 38538977
[TBL] [Abstract][Full Text] [Related]
53. Salvage chemotherapy followed by granulocyte colony-stimulating factor-primed donor leukocyte infusion with graft-vs.-host disease control for minimal residual disease in acute leukemia/myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation: prognostic factors and clinical outcomes.
Mo XD; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YH; Han W; Wang FR; Wang JZ; Liu KY; Huang XJ
Eur J Haematol; 2016 Mar; 96(3):297-308. PubMed ID: 26010204
[TBL] [Abstract][Full Text] [Related]
54. Reduced intensity conditioning regimen of fludarabine, busulfan, ATG based haploidentical stem cell transplantation for older or unfit patients.
Pan M; Wu Y; Yang L; Zhu P; Shi J; Lai X; Liu L; Zhao Y; Yu J; Huang H; Luo Y
Ann Hematol; 2024 Jun; ():. PubMed ID: 38829409
[TBL] [Abstract][Full Text] [Related]
55. Outcome of haploidentical versus matched sibling donors in hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Nagler A; Labopin M; Houhou M; Aljurf M; Mousavi A; Hamladji RM; Al Zahrani M; Bondarenko S; Arat M; Angelucci E; Koc Y; Gülbas Z; Sica S; Bourhis JH; Canaani J; Brissot E; Giebel S; Mohty M
J Hematol Oncol; 2021 Apr; 14(1):53. PubMed ID: 33794963
[TBL] [Abstract][Full Text] [Related]
56. HLA-haploidentical peripheral blood stem cell transplantation following reduced-intensity conditioning with very low-dose antithymocyte globulin for relapsed/refractory acute leukemia in pediatric patients: a single-institution retrospective analysis.
Higuchi K; Sawada A; Kondo O; Okada Y; Tsujimoto H; Ioi A; Mayumi A; Shimizu M; Sato M; Goto K; Inoue S; Yasui M; Inoue M
Int J Hematol; 2022 Mar; 115(3):406-413. PubMed ID: 35028882
[TBL] [Abstract][Full Text] [Related]
57. Prophylactic Donor Lymphocyte Infusion (DLI) Followed by Minimal Residual Disease and Graft-versus-Host Disease-Guided Multiple DLIs Could Improve Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Refractory/Relapsed Acute Leukemia.
Yan CH; Liu QF; Wu DP; Zhang X; Xu LP; Zhang XH; Wang Y; Huang H; Bai H; Huang F; Ma X; Huang XJ
Biol Blood Marrow Transplant; 2017 Aug; 23(8):1311-1319. PubMed ID: 28483716
[TBL] [Abstract][Full Text] [Related]
58. [Increased risk of severe acute graft-versus-host disease in low body mass index patients undergoing haploidentical allogeneic stem cell transplantation].
Chen Y; Xu L; Liu D; Liu K; Chen H; Zhang X; Wang F; Wang J; Wang Y; Han W; Chen Y; Yan C; Zhao T; Huang X
Zhonghua Nei Ke Za Zhi; 2014 Sep; 53(9):710-4. PubMed ID: 25511404
[TBL] [Abstract][Full Text] [Related]
59. T-cell-replete haploidentical stem cell transplantation using low-dose antithymocyte globulin in children with relapsed or refractory acute leukemia.
Sano H; Mochizuki K; Kobayashi S; Ohara Y; Ito M; Waragai T; Takahashi N; Ikeda K; Ohto H; Kikuta A
Int J Hematol; 2018 Jul; 108(1):76-84. PubMed ID: 29508228
[TBL] [Abstract][Full Text] [Related]
60. Different effects of thymoglobulin on acute leukemia with pre-transplant residual blasts in HLA mismatch transplantation.
Wakamatsu M; Murata M; Kanda J; Fukushima K; Fukuda T; Najima Y; Katayama Y; Ozawa Y; Tanaka M; Kanda Y; Eto T; Takada S; Kako S; Uchida N; Kawakita T; Yoshiko H; Ichinohe T; Atsuta Y; Terakura S;
Int J Hematol; 2023 Jun; 117(6):889-899. PubMed ID: 36814041
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
